Difference between revisions of "Axitinib (Inlyta)"
m (→Also known as) |
(updated content) |
||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.inlyta.com/ | + | *[http://www.inlyta.com/side-effect-tips Inlyta Side Effect Tips & Videos (Pfizer)]<ref>[http://www.inlyta.com/side-effect-tips Inlyta Side Effect Tips & Videos (Pfizer)]</ref> |
| + | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]<ref name="insert"></ref> | ||
*[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]</ref> | ||
| Line 19: | Line 20: | ||
==Also known as== | ==Also known as== | ||
| − | AG013736, AG-013736 | + | AG013736, AG-013736. |
==References== | ==References== | ||
Revision as of 17:06, 28 December 2014
General information
Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Inlyta Side Effect Tips & Videos (Pfizer)[4]
- Axitinib (Inlyta) package insert[1]
- Axitinib (Inlyta) patient drug information (Chemocare)[5]
- Axitinib (Inlyta) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 1/27/2012: Initial FDA approval "for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy."
Also known as
AG013736, AG-013736.
References
- ↑ 1.0 1.1 1.2 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Inlyta Side Effect Tips & Videos (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)